Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 4Phase 1 2

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Has results × relugolix × Clear all
NCT04523207 2026-04-21

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Janssen Research & Development, LLC

Phase 2 Completed
108 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT05320406 2026-02-12

REVELUTION

Emory University

Phase 2 Active not recruiting
94 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT02083185 2018-05-09

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

Takeda

Phase 2 Completed
136 enrolled 26 charts
Genitourinary

Prostatic Neoplasms

NCT02135445 2017-04-13

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

Takeda

Phase 2 Completed
103 enrolled 42 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡